Patent US4355031A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4355031A Expired / Lapsed US ⏱️ 0.0 years remaining

2,3-Dihydro-3-[4-(substituted)-1-piperazinyl]-1H-isoindol-1-ones

Assignee: Wyeth LLC
•
Filing: 1981-05-11
•
Granted: 1982-10-19
•
Expires: 2001-05-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Pyrazinoisoindolone derivatives of the formula ##STR1## wherein R 1 is lower alkyl, phenyl, diphenylmethyl, pyridinyl, pyrimidinyl, pyrazinyl or pyrazinyl substituted with a lower alkyl, lower alkoxy or halo; and R 2 is hydrogen, lower alkyl or di(lower)alkylamino(lower)alkyl are useful as antihypertensive agents.

Inventors

  • 👤 Christopher A. Demerson
  • 👤 Ivo L. Jirkovsky

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 17:32
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/44; C07D209/50

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 34 words
A compound of formula I ##STR4## wherein R 1 is lower alkyl, phenyl, diphenylmethyl, or pyridinyl; and R 2 is hydrogen, lower alkyl or di(lower)alkylamino(lower) alkyl; or a therapeutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim 34 words
A compound of formula I ##STR4## wherein R 1 is lower alkyl, phenyl, diphenylmethyl, or pyridinyl; and R 2 is hydrogen, lower alkyl or di(lower)alkylamino(lower) alkyl; or a therapeutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim 23 words
The compound of claim 1 wherein R 1 is lower alkyl, phenyl, diphenylmethyl, 2-pyridinyl, 4-pyridinyl; or a therapeutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim 32 words
The compound of claim 1 wherein R 1 is methyl, phenyl, diphenylmethyl, 2-pyridinyl, 4-pyridinyl; and R 2 is methyl, ethyl, 1-methylethyl, (N,N-dimethylamino)ethyl or (N,N-dimethylamino)propyl; or a therapeutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim 28 words
The compound of claim 1 wherein R 1 is 2-pyridinyl or 4-pyridinyl and R 2 is lower alkyl or di(lower)alkylamino(lower)alkyl, or a therapeutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim 6 words
2,3-Dihydro-3-(4-methyl-1-piperazinyl)-1H-isoindol-1-one, as claimed in claim 1.
Claim 7
Dependent Claim 6 words
2,3-Dihydro-3-[4-(4-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 8
Dependent Claim 6 words
2,3-Dihydro-3-[4-(diphenylmethyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 9
Dependent Claim 6 words
2,3-Dihydro-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 10
Dependent Claim 6 words
2,3-Dihydro-3-(4-phenyl-1-piperazinyl)-1H-isoindol-1-one, as claimed in claim 1.
Claim 11
Dependent Claim 6 words
2,3-Dihydro-2-(1-methylethyl)-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 12
Dependent Claim 6 words
2,3-Dihydro-2-[(N,N-dimethylamino)propyl]-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 13
Dependent Claim 6 words
2,3-Dihydro-2-[(N,N-dimethylamino)ethyl]-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 14
Dependent Claim 6 words
2,3-Dihydro-2-ethyl-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 15
Dependent Claim 6 words
2,3-Dihydro-2-methyl-3-[4-(2-pyridinyl)-1-piperazinyl]-1H-isoindol-1-one, as claimed in claim 1.
Claim 16
Dependent Claim 25 words
An antihypertensive pharmaceutical composition which comprises a compound of claim 1, or a therapeutically acceptable acid addition salt thereof, and a pharmaceutically acceptable carrier therefor.
Claim 17
Dependent Claim 33 words
A method of treating hypertension in a hypertensive mammal which comprises administering to said mammal an effective antihypertensive amount of a compound of claim 1 or a therapeutically acceptable acid addition salt thereof.

References Cited (Backward Citations)

CH374068A Cited
US3579524A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-10-18 1986-04-19 1986-10-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-10-18 1990-04-19 1990-10-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-10-18 1994-04-19 1994-10-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag